Meeting
2016 ASCO Annual Meeting
Cardiac safety analysis of trabectedin (T) vs. dacarbazine (D) in patients (Pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) after prior anthracycline chemotherapy.
Authors
Scott Schuetze
University of Michigan, Ann Arbor, MI
Scott Schuetze , Shreyaskumar Patel , Margaret von Mehren , Christopher W. Ryan , Mohammed M. Milhem , Brian Andrew Van Tine , Sharon Anne McCarthy , George C. Wang , Loreta Marquez , Trilok V. Parekh , Roland Elmar Knoblauch , George D. Demetri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT01343277
Citation
J Clin Oncol 34, 2016 (suppl; abstr 11060)
DOI
10.1200/JCO.2016.34.15_suppl.11060
Abstract #
11060
Poster Bd #
186
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Patient-reported outcomes from randomized, phase-3 study of trabectedin (T) vs. dacarbazine (D) in advanced leiomyosarcoma (LMS) or liposarcoma (LPS).
First Author: George D. Demetri
Poster
2016 ASCO Annual Meeting
Trabectedin for advanced soft-tissue sarcoma: A single-center experience of over 10 years.
First Author: Imran Syed
Poster
2022 ASCO Annual Meeting
Trabectedin in advanced retroperitoneal well differentiated/dedifferentiated liposarcoma and leiomyosarcoma (TRAVELL): Results of a phase 2 study from Italian sarcoma group (ISG).
First Author: Roberta Sanfilippo
